Visual acuity outcomes in Coats disease by classification stage in 160 patients

RECOMMENDED

Macular Diseases

VISUAL ACUITY IN PATIENTS WITH STARGARDT DISEASE AFTER AGE 40

Retina.

Collison FT, Fishman GA

doi: 10.1097/IAE.

Macular Diseases

Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register

Acta Ophthalmol.

Lövestam Adrian M, Vassilev ZP, Westborg I

doi: 10.1111/aos.13864.

Macular DiseasesRetinal Diseases

Contrast sensitivity function in patients with macular disease and good visual acuity

Br J Ophthalmol

Wai KM, Vingopoulos F, Garg I, Kasetty M, Silverman RF, Katz R, Laíns I, Miller JW, Husain D, Vavvas DG, Kim LA, Miller JB

doi: 10.1136/bjophthalmol-2020-318494

Blindness and Vision ImpairmentGlaucoma and Ocular PressureOcular Oncology

Twenty-year outcomes in patients with newly diagnosed glaucoma: mortality and visual function

Br J Ophthalmol.

King C, Sherwin JC, Ratnarajan G, Salmon JF

doi: 10.1136/bjophthalmol-

Macular Diseases

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Eye (Lond).

Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.

doi: 10.1038/s41433-018-0114-3.

Visual Function in Asymptomatic Patients With Homozygous Sickle Cell Disease and Temporal Macular Atrophy

JAMA Ophthalmol.

Martin GC, Dénier C, Zambrowski O, Grévent D, Bruère L, Brousse V, de Montalembert M, Brémond-Gignac D, Robert MP

doi: 10.1001/

Ocular Oncology

Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy

JAMA Ophthalmol.

Shields CL, Sioufi K, Srinivasan A, DiNicola M, Masoomian B, Barna LE, Bekerman VP, Say EAT, Mashayekhi A, Emrich J, Komarnicky L, Shields JA

doi: 10.1001/jamaophthalmol.

Macular Diseases

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Ophthalmol Retina.

Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.

doi: 10.1016/j.oret.2019.06.001.

Macular DiseasesOcular OncologyRetinal Diseases

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients

Br J Ophthalmol.

Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, Shields CL

doi: 10.1136/bjophthalmol-2019-314686.

Related content

VISUAL ACUITY IN PATIENTS WITH STARGARDT DISEASE AFTER AGE 40

Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register

Contrast sensitivity function in patients with macular disease and good visual acuity

Twenty-year outcomes in patients with newly diagnosed glaucoma: mortality and visual function

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Visual Function in Asymptomatic Patients With Homozygous Sickle Cell Disease and Temporal Macular Atrophy

Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients